Table 3.
Cox Regressions of Survival by Anti-viral IgG Seropositivity, San Francisco Bay Area Adult Glioma Study
| Overall Glioma | Grades II and III Glioma | Grade IV Glioma | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n Cases | n Died | Median Months Survival | P | n Cases | n Died | Median Months Survival | P | n Cases | n Died | Median Months Survival | P | |
| HR (95% CI)a | HR (95% CI)a | HR (95% CI)a | ||||||||||
| IgG for VZV | 1374 | 1072 | .0061 0.70 (0.54–0.90) |
480 | 278 | .226 0.70 (0.40–1.24) |
760 | 739 | .0046 0.65 (0.48–0.87) |
|||
| Negative | 78 | 63 | 18.8 | 22 | 13 | 102.0 | 47 | 47 | 11.8 | |||
| Positive | 1296 | 1009 | 25.7 | 458 | 265 | 133.0 | 713 | 692 | 16.1 | |||
| IgG for CMV | 781 | 640 | .213 1.11 (0.94–1.31) |
293 | 196 | .386 1.14 (0.84–1.55) |
415 | 411 | .758 1.03 (0.84–1.27) |
|||
| Negative | 353 | 284 | 25.3 | 137 | 90 | 135.8 | 184 | 182 | 14.4 | |||
| Positive | 428 | 356 | 20.0 | 156 | 106 | 98.7 | 231 | 229 | 13.4 | |||
| IgG for EBV | 781 | 640 | .028 0.71 (0.53–0.96) |
293 | 196 | .322 0.77 (0.47–1.28) |
415 | 411 | .154 0.75 (0.50–1.12) |
|||
| Negative | 58 | 48 | 17.8 | 24 | 17 | 99.3 | 27 | 27 | 13.4 | |||
| Positive | 723 | 592 | 22.5 | 269 | 179 | 119.4 | 388 | 384 | 14.0 | |||
| IgG for HSV | 775 | 634 | .215 1.13 (0.93–1.36) |
290 | 193 | .163 1.27 (0.91–1.77) |
412 | 408 | .367 1.12 (0.88–1.42) |
|||
| Negative | 211 | 165 | 31.4 | 90 | 57 | 142.0 | 96 | 96 | 15.7 | |||
| Positive | 564 | 469 | 20.0 | 200 | 136 | 111.0 | 316 | 312 | 13.7 |
aHR adjusted for age, sex, race (white/nonwhite), series, surgery (resection/biopsy only), and dexamethasone usage; Overall glioma models include stratification by tumor grade. Hazard ratio for seropositive individuals.